References
- World Health Organization (WHO). Cancer: key facts. 2018. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed 2 November 2019.
- Global Burden of Disease Cancer Collaboration. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 Cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–1568.
- Bhandari GP, Angdembe MR, Dhimal M, Neupane S, Bhusal C. State of non-communicable diseases in Nepal. BMC Public Health. 2014;14(1):23.
- International Agency for Research on Cancer. Nepal Fact sheet: GLOBOCAN 2018. http://gco.iarc.fr/today/data/factsheets/populations/524-nepal-fact-sheets.pdf. Assessed 18 June 2019).
- Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, González-Fernández Á. Assessment of the evolution of cancer treatment therapies. Cancers. 2011;3(3):3279–3330.
- Danzon PM, Taylor E. Drug pricing and value in oncology. Oncologist. 2010;15(Supplement 1):24–31.
- Salmasi S, Lee KS, Ming LC, Neoh CF, Elrggal ME, Khan TM, Hadi MA. Pricing appraisal of anti-cancer drugs in the south east Asian, Western Pacific and East Mediterranean region. BMC Cancer. 2017;17(1):903.
- Vogler S, Vitry A. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2016;17(1):39–47.
- Kolasani BP, Malathi DC, Ponnaluri RR. Variation of cost among anti-cancer drugs available in Indian market. J Clin Diagn Res. 2016;10(11):FC17.
- The Kathmandu Post. Health insurance plan yet to cover 38 districts in Nepal, 2018. [cited 2019 31 July]; Available from: https://kathmandupost.com/national/2018/06/07/health-insurance-plan-yet-to-cover-38-districts-in-nepal. Accessed 31 July 2019.
- Mishra SR, Khanal P, Karki DK, Kallestrup P, Enemark U. National health insurance policy in Nepal: challenges for implementation. Glob Health Action. 2015;8(1):28763.
- Government of Nepal, Ministry of Health and Population. Medical Treatment of Deprived Citizens. https://www.mohp.gov.np/eng/program/medical-treatment-deprived-citizen. Accessed 29 July 2019.
- Khatiwoda SR, Dhungana RR, Sapkota VP, Singh S. Estimating the direct cost of Cancer in Nepal: a cross-sectional study in a tertiary Cancer hospital. Front Public Health. 2019;7:160.
- Piya MK, Acharya SC. Oncology in Nepal. South Asian J Cancer. 2012;1(1):5.
- Swe KT, Rahman MM, Rahman MS, Saito E, Abe SK, Gilmour S, Shibuya K. Cost and economic burden of illness over 15 years in Nepal: a comparative analysis. PLoS One. 2018;13(4):e0194564.
- Saito E, Gilmour S, Rahman MM, Gautam GS, Shrestha PK, Shibuya K. Catastrophic household expenditure on health in Nepal: a cross-sectional survey. Bull World Health Organ. 2014;92:760–767.
- Department of Drug Administration, MRP of medicines, 2018. http://www.dda.gov.np/content/mrp-of-medicines. Accessed 30 July 2019.
- Poudel RS, Poudel BK, Shrestha S, Piryani RM. Variation in prices of medicines used for the long-term management of non-communicable diseases available in the pharmacy of a tertiary care hospital of Nepal. J Pharm Health Serv Res. 2018;9(4):293–296.
- Devkota A, Paudel A, Koirala B, Baral D, Gautam S, Sharma SK. Price variation and availability of free medicine for non-communicable diseases. J Nepal Health Res Counc. 2018;16(2):118–123.
- Mishra SR, Kandel N, Subedi N, Khanal V. Variation in prices of cardiovascular drugs in public and private pharmacies in Nepal. Health Serv Res Manag Epidemiol. 2015;2:1–4.
- Department of Drug Administration. List of Domestic industries listed in DAMS till 4/10/2018, 2018. http://www.dda.gov.np/content/list-of-domestic-industries-listed-in-dams-till-4-10-2018. Accessed 31 July 2019.
- Goodman LS. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill; 2011.
- Department of Drug Administration. Drug Act, 2035 (1978). http://www.dda.gov.np/content/drugs-act-2035. Accessed 30 July 2019.
- Ranjit E. Pharmacy practice in Nepal. Can J Hosp Pharm. 2016;69(6):493.
- National List Of Essential Medicines Nepal (Fifth Revision) 2016. http://apps.who.int/medicinedocs/documents/s23537en/s23537en.pdf. Accessed 10 November 2019.
- Shankar P, et al. Hospital pharmacy services in teaching hospitals in Nepal: challenges and the way forward. Arch Med Health Sci. 2016;4(2):212–217.
- Adwal SK, Baghel R. Price variation in different brands of anticancer drugs available in Indian pharmaceutical market: a cost analysis study. Int J Basic Clin Pharmacol. 2019;8(4):642..
- Tadesse N, Fang Y. PCN231-pricing, availability, affordability, Price components of essential anticancer medicines in Addis Ababa, Ethiopia. Value Health. 2018;21:S53.
- Ansari M, Humagain B, Hassali M. Generic medicines utilizations and generic prescribing in Nepal: a reflection of current scenario and possible solutions. Res Soc Adm Pharm. 2017;13(3):658–659.
- Panth N, Paudel KR, Chaudhary B, Thapa KK. A Study On The Price Variability Among The Oral Antibiotics Available In A Western Region Hospital-A Context Of Nepal. World J Pharm Pharm Sci. 2014;3(3):1529–1535.
- Poudel BK, Ishii I. Regulation of the price of medicines in developing countries: the case in Nepal. J Pharm Pract Res. 2017;47(4):319–320.
- World Health Organisation/Health Action Internation Project on Medicine Prices and Availability. Review Series on Pharmaceutical Pricing Policies and Interventions. May 2011. https://haiweb.org/wp-content/uploads/2015/08/Competition-final-May-2011a1.pdf. Accessed 10 January 2020.
- Dabora MC, Turaga N, Schulman KA. Financing and distribution of pharmaceuticals in the United States. JAMA. 2017;318(1):21–2.
- Goldsbury DE, Yap S, Weber MF, Veerman L, Rankin N, Banks E, Canfell K, O’Connell DL. Health services costs for cancer care in Australia: estimates from the 45 and up study. PLoS One. 2018;13(7):e0201552.
- Olejaz M, Juul AN, Rudkjøbing A, Okkels HB, Krasnik A, Hernández-Quevedo C. Denmark health system review. Health Syst Transit. 2012;14(2):i–xxii.
- Ministry of Health and Population in collaboration with the World Health Organization. Nepal Pharmaceutical Country Profile, Ministry of Health and Population in collaboration with the World Health Organization. 2011 https://www.who.int/medicines/areas/coordination/nepal_pharmaceutical_profile.pdf. Accessed 31 July 2019.
- Abdel Rida N, Mohamed Ibrahim MI, Babar ZU, Owusu Y. A systematic review of pharmaceutical pricing policies in developing countries. J Pharm Health Serv Res. 2017;8(4):213–226.
- World Health Organization, WHO guideline on country pharmaceutical pricing policies, World Health Organization 2015. https://apps.who.int/medicinedocs/documents/s21016en/s21016en.pdf. Accessed 29 June 2019.
- Manufacturing Chemist. Getting drug pricing right. 2017 https://www.manufacturingchemist.com/news/article_page/Getting_drug_pricing_right/136813. Accessed 7 November 2019.
- Hinsch M, Kaddar M, Schmitt S. Enhancing medicine price transparency through price information mechanisms. Glob Health. 2014;10(1):34.
- Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pract. 2017;6:37.
- Shrestha S, Shrestha S, Palaian S. Can clinical pharmacists bridge a gap between medical oncologists and patients in resource-limited oncology settings? An experience in Nepal. J Oncol Pharm Pract. 2019;25(3):765–768.
- Cowper PA, Weinberger M, Hanlon JT, Landsman PB, Samsa GP, Uttech KM, Schmader KE, Lewis IK, Cohen HJ, Feussner JR. The cost-effectiveness of a clinical pharmacist intervention among elderly outpatients. Pharmacotherapy. 1998;18(2):327–332.
- Marra C, Johnston K, Santschi V, Tsuyuki RT. Cost-effectiveness of pharmacist care for managing hypertension in Canada. Can Pharm J (Ott). 2017;150(3):184–197.